Optibrium partners with TalTech on EU-Funded PhD Programme to advance sustainable drug discovery
The research will focus on developing faster and more accurate methods for predicting drug metabolism
Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery
Study identifies new metrics to enhance scRNA-seq based virtual cell modellingFoundational paper to drive development of improved virtual cell models for rejuvenation target discoveryCambr
4basebio introduces new branding to reflect next phase of growth enabling development of advanced genetic therapies
4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, today (01 July 2025) announced refreshed branding and the launch of its new website, reflecting the company’s continued growth and success in this rapidly advancing field.
Zyme Communications celebrates 15 years of providing specialist support for the life science sector
Zyme Communications Ltd. (Zyme), the life science specialist PR and marketing agency, today (26 June 2025) celebrates its 15-year anniversary, and introduces refreshed branding to reflect this milestone and the Company’s continued development.
Enhanced Genomics and The ALBORADA Drug Discovery Institute partner to accelerate Alzheimer's drug discovery
Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced a strategic partnership with The ALBORADA Drug Discovery Institute at the University of
OutSee raises £1.8M seed funding to expand therapeutic pipeline using predictive genomics
Financing led by Ahren Innovation Capital with additional investment from Kadmos Capital, Empirical Ventures and Panacea VenturesInvestment to leverage OutSee’s proprietary AI-based predictive genomics technology, Nomaly, to expand and progress in-house target developme
Bio-Rad extends anti-idiotypic antibody and SpyCatcher Reagent ranges for bioanalysis and antibody drug development
Additions to Company’s Range of Bioanalytical Antibodies and Reagents Enhances Bioanalysis and Antibody-Related Research
Qureight’s synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment
AI-enabled analytics platform demonstrates how real-world data used in place of human placebo and control groups can significantly reduce study costs and duration
Mursla Bio introduces AI precision medicine platform built on organ-specific EV isolation from blood
Platform is built on biologically labelled, organ-specific multi-omics data carried by extracellular vesicles isolated from 2ml plasma samplesEnables differentiated AI-powered biomarker discovery and IVD translation for patient stratification, therapeutic monitoring, su
SolasCure receives FDA Fast Track Designation for Aurase Wound Gel to treat calciphylaxis ulcers
Recognises the potential of Aurase Wound Gel to improve outcomes for individuals with calciphylaxis ulcers, a rare and life-threatening conditionRepresents a new indication for Aurase Wound Gel, currently in Phase II Clinical Trials for treatment of venous leg ulcers
Kadans Science Partner completes construction of primary structure on purpose built laboratory building at Merlin Place, North Cambridge
Topping out ceremony gathered key stakeholders on Cambridge Wide Open Day to celebrate progress in development of new laboratory facilities139,000 sq ft of flexible lab and office space, due for completion Q3 2026Cambridge, UK, 13 June 2025:
Enhanced Genomics appoints Dietrich Stephan, Ph.D. as Chair of the Board to lead ambitious growth strategy
Appointment strengthens leadership team to drive strategy focused on harnessing 3D multi-omics to identify high-confidence, high-value therapeutic targets, to accelerate drug discovery
Tagomics awarded £860k Innovate UK Biomedical Catalyst grant for detection of colorectal cancer
Grant forms part of £1.2M project to customise Tagomics’ multiomic profiling platform for early detection of colorectal cancerEarly detection test to be developed in collaboration with the Salford Royal NHS Foundation Trust and the Northern Care Alliance Research Collection biobank
Centauri Therapeutics publishes proof-of-concept data demonstrating activity of a novel bifunctional immunotherapy against Gram-negative bacterial infections
Paper presents the first pre-clinical application of endogenous antibody recruitment to address multi-drug resistant Gram-negative infectionsNovel bifunctional molecule based on Alphamer platform demonstrated direct, broad-spectrum antibacterial activity in vitro and in vivo, with e
Shift Bioscience identifies novel single-gene target for safer cellular rejuvenation therapeutics
SB000 reverses cellular ageing as measured by DNA methylation clocks in multiple cell types without loss of cellular identity or signs of pluripotencyStudy advances efforts towards next-generation rejuvenation therapeutics with applications across age-driven diseas
Fujifilm rebrands life sciences companies to strengthen position as strategic Partners for Life, offering end-to-end solutions
FUJIFILM Irvine Scientific becomes FUJIFILM Biosciences, providing a full spectrum of life sciences solutions built from a 55-year history as a cell culture pioneer FUJIFILM Diosynth Biotechnologies will be known as FUJIFILM Biotechnologies, serving global partners seek
Sapio Sciences appoints Gordon McCall as Chief Operating Officer to drive global operational excellence
New role underscores Sapio’s commitment to operational excellence and elevating customer delivery across global markets
Closed Loop Medicine appoints Kate Woolland as CEO
Leadership transition to drive commercialization strategy in deploying and scaling proven platform and therapy-specific precision dosing technologies
Shift Bioscience appoints Lord David Prior and Sir Tony Kouzarides to support long-term strategy for cell rejuvenation therapeutics
Lord David Prior appointed as Chair of the Board, previously Chairman of NHS England and member of the UK Life Sciences Council Sir Tony Kouzarides, Co-founder and Director, Milner Therapeutics Institute, and Professor of Cancer Biology, Gurdon Institute, appointed as S
Tozaro announces formation of Technical Advisory Board to support commercialization of Smart Polymers in cell and gene therapy bioprocessing
World-class experts from bioprocessing and cell and gene therapy (CGT) fields include Phil Vanek PhD, Carl Schoellhammer PhD, Daniel C.
PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics
Barbara Duncan joins as Chair and Stephen Dilly as Non-Executive DirectorStrategic appointments support progression of PhoreMost’s next generation degrader pipeline through preclinical development and commercialisation of its GlueSEEKER® platform
Trilobio raises $8M to deliver whole lab automation for biologists
San Francisco, US, 06 May 2025: Trilobio, the Company building the fully automated robotic lab-in-a-box for biologists, announces it has raised $8 million USD Seed investment.
PlaqueTec announces positive early research findings from interim analysis in BIOPATTERN trial
Pre-specified interim analysis reveals differences in protein concentration between systemic blood and blood from diseased coronary arteries
Tozaro appoints Dr. Jason Slingsby MBA as CEO to lead company strategy in cell and gene therapy sector
Established biotech leader with over 20 years’ experience including at OXB and LifeArc driving commercialization to support CGT downstream manufacturingMichele Pedrocchi PhD appointed as Non-Executive Chair of the Board of DirectorsBedfordshire
Sapio Sciences introduces Biorepository Management Solution in Sapio Release 25.4
Latest release of Sapio Platform streamlines sample workflows and delivers centralized, compliant biospecimen management